Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIAD 7 trial of recombinant interleukin-7 in lymphopenic hospitalized COVID-19 patients
2020-001786-36Phase 2Unknown
- Sponsor
- RevImmune
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing CYT107 with Placebo (2 arms). Primary endpoint: Improvement in absolute lymphocyte count. Status: unknown.
02
Drugs
recombinant human interleukin-7
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001786-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001786-36.